Pharmacology of Parkinson's disease.
The approach to treatment of Parkinson's disease depends on the severity of symptoms at presentation and the response to previous therapy. The pharmacotherapy of Parkinson's disease is discussed with respect to management of cardinal symptoms, management of associated features, and future directions for therapy.
D000547:Amantadine / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001708:Biopterins / Q000031:analogs & derivatives / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D006634:Histamine H1 Antagonists; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D001708:Biopterins; D007980:Levodopa; D000547:Amantadine; C003402:sapropterin; D004298:Dopamine; D009638:Norepinephrine